MicroStrategy
MSTR
Adobe
ADBE
Salesforce
CRM
Apple
AAPL
Meritage Homes
MTH
US Stock MarketDetailed Quotes
ATRA Atara Biotherapeutics
- 11.400
- +1.470+14.80%
Close Dec 20 16:00 ET
- 11.550
- +0.150+1.32%
Post 20:01 ET
65.66MMarket Cap-0.45P/E (TTM)
11.470High9.862Low152.32KVolume10.430Open9.930Pre Close1.69MTurnover3.25%Turnover RatioLossP/E (Static)5.76MShares39.50052wk High-0.73P/B53.41MFloat Cap6.50052wk Low--Dividend TTM4.69MShs Float1638.998Historical High--Div YieldTTM16.20%Amplitude4.965Historical Low11.088Avg Price1Lot Size
Atara Biotherapeutics Key Stats
Quarterly+Annual
YOY
| (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 1,779.79%40.19M | 2,892.69%28.64M | 2,131.40%27.36M | -86.51%8.57M | 1,823.98%4.25M | -52.05%2.14M | -98.14%957K | -83.24%1.23M | 212.55%63.57M | -97.07%221K |
| Operating revenue | 1,779.79%40.19M | 2,892.69%28.64M | 2,131.40%27.36M | -86.51%8.57M | 1,823.98%4.25M | -52.05%2.14M | -98.14%957K | -83.24%1.23M | 212.55%63.57M | -97.07%221K |
| Cost of revenue | 190.71%7.6M | 59.83%4.63M | 818.98%1.99M | 8.89M | 3.16M | 2.62M | 2.9M | 216K | 0 | 0 |
| Gross profit | 6,931.87%32.59M | 1,339.06%24.01M | 2,412.08%25.37M | -100.49%-313K | 394.12%1.09M | -110.70%-477K | -103.76%-1.94M | -86.19%1.01M | 63.57M | 221K |
| Operating expense | -21.39%54.35M | -39.20%42.24M | -25.53%56.62M | -19.88%275.69M | -19.41%61.05M | -22.39%69.14M | -17.00%69.48M | -20.42%76.03M | -4.63%344.09M | -24.95%75.76M |
| Selling and administrative expenses | -14.91%10.42M | -33.17%8.91M | -19.89%11.11M | -28.85%50.91M | -13.52%11.45M | -35.28%12.25M | -29.12%13.34M | -32.57%13.87M | -9.20%71.55M | -39.29%13.25M |
| -General and administrative expense | -14.91%10.42M | -33.17%8.91M | -19.89%11.11M | -28.85%50.91M | -13.52%11.45M | -35.28%12.25M | -29.12%13.34M | -32.57%13.87M | -9.20%71.55M | -39.29%13.25M |
| Research and development costs | -22.79%43.92M | -40.63%33.33M | -26.79%45.51M | -17.52%224.79M | -20.66%49.6M | -18.91%56.89M | -13.49%56.14M | -17.08%62.16M | -3.36%272.53M | -21.00%62.52M |
| Operating profit | 68.75%-21.76M | 74.47%-18.23M | 58.35%-31.25M | 1.61%-276.01M | 20.62%-59.96M | 17.74%-69.61M | -122.25%-71.41M | 14.96%-75.02M | 17.61%-280.51M | 19.13%-75.54M |
| Net non-operating interest income expense | -309.04%-724K | -356.15%-812K | -217.81%-549K | -94.75%141K | -144.80%-465K | -120.82%-177K | -44.87%317K | 108.04%466K | 631.88%2.69M | 1,135.71%1.04M |
| Non-operating interest income | -62.32%459K | -73.45%450K | -66.48%604K | 77.38%5.43M | -38.44%711K | 25.18%1.22M | 140.77%1.7M | 690.35%1.8M | 733.51%3.06M | --1.16M |
| Non-operating interest expense | -15.20%1.18M | -8.42%1.26M | -13.70%1.15M | 1,316.89%5.29M | 905.13%1.18M | 1,034.15%1.4M | 968.22%1.38M | 33,300.00%1.34M | --373K | --117K |
| Other net income (expense) | 2,155.56%555K | 40.00%-6K | 134.52%68K | -100.50%-246K | 82.61%-12K | 91.26%-27K | -100.02%-10K | -80.73%-197K | 49.54M | -69K |
| Special income (charges) | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- | --50.24M | --0 |
| -Gain on sale of property,plant,equipment | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- | --50.24M | --0 |
| Other non- operating income (expenses) | 2,155.56%555K | 40.00%-6K | 134.52%68K | 64.86%-246K | 82.61%-12K | 91.26%-27K | 95.33%-10K | -80.73%-197K | ---700K | ---69K |
| Income before tax | 68.59%-21.93M | 73.21%-19.05M | 57.55%-31.73M | -20.95%-276.11M | 18.95%-60.44M | 16.97%-69.82M | -485.07%-71.11M | 15.16%-74.75M | 32.87%-228.29M | 20.09%-74.57M |
| Income tax | 10.53%-17K | 0 | 9.09%24K | 25.00%15K | 450.00%11K | -290.00%-19K | 1K | 22K | -73.91%12K | -93.33%2K |
| Net income | 68.61%-21.91M | 73.21%-19.05M | 57.53%-31.75M | -20.95%-276.13M | 18.94%-60.45M | 17.00%-69.8M | -485.08%-71.11M | 15.13%-74.77M | 32.88%-228.3M | 20.11%-74.57M |
| Net income continuous Operations | 68.61%-21.91M | 73.21%-19.05M | 57.53%-31.75M | -20.95%-276.13M | 18.94%-60.45M | 17.00%-69.8M | -485.08%-71.11M | 15.13%-74.77M | 32.88%-228.3M | 20.11%-74.57M |
| Minority interest income | ||||||||||
| Net income attributable to the parent company | 68.61%-21.91M | 73.21%-19.05M | 57.53%-31.75M | -20.95%-276.13M | 18.94%-60.45M | 17.00%-69.8M | -485.08%-71.11M | 15.13%-74.77M | 32.88%-228.3M | 20.11%-74.57M |
| Preferred stock dividends | ||||||||||
| Other preferred stock dividends | ||||||||||
| Net income attributable to common stockholders | 68.61%-21.91M | 73.21%-19.05M | 57.53%-31.75M | -20.95%-276.13M | 18.94%-60.45M | 17.00%-69.8M | -485.08%-71.11M | 15.13%-74.77M | 32.88%-228.3M | 20.11%-74.57M |
| Basic earnings per share | 82.13%-2.93 | 81.67%-3.1 | 68.06%-5.75 | -16.52%-65.25 | 22.33%-13.98 | 20.00%-16.4 | -475.78%-16.91 | 17.24%-18 | 38.29%-56 | 25.00%-18 |
| Diluted earnings per share | 82.13%-2.93 | 81.67%-3.1 | 68.06%-5.75 | -16.52%-65.25 | 22.33%-13.98 | 20.00%-16.4 | -475.78%-16.91 | 17.24%-18 | 38.29%-56 | 25.00%-18 |
| Dividend per share | ||||||||||
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- |
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
